How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

11,201 results for

Glucagon

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Is Glucagon Effective for Relieving Acute Esophageal Foreign Bodies and Food Impactions? Full Text available with Trip Pro

Is Glucagon Effective for Relieving Acute Esophageal Foreign Bodies and Food Impactions? Is Glucagon Effective for Relieving Acute Esophageal Foreign Bodies and Food Impactions? - Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page To read this article in full, please review your options for gaining access at the bottom of the page. Article in Press Is Glucagon Effective for Relieving Acute Esophageal Foreign Bodies and Food (...) Impactions? x Brit Long , MD (EBEM Commentator) Department of Emergency Medicine, San Antonio Uniformed Services Health Education Consortium, Fort Sam Houston, TX x Michael Gottlieb , MD, RDMS (EBEM Commentator) Department of Emergency Medicine, Rush Medical Center, Chicago, IL DOI: Publication History Published online: May 09, 2019 To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Glucagon is not associated with improved treatment success

2019 Annals of Emergency Medicine Systematic Review Snapshots

3. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Full Text available with Trip Pro

Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. The projected rise in the incidence of type 2 diabetes mellitus (T2DM) could develop into a substantial health problem worldwide. Whether dipeptidyl-peptidase (DPP)-4 inhibitors or glucagon-like peptide (GLP)-1 analogues are able to prevent or delay

2017 Cochrane

5. Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome

Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation HAYES, Inc. Glucagon-like peptide-1 receptor agonists for the treatment of obesity in women with polycystic ovary syndrome. Lansdale: HAYES, Inc. Healthcare Technology Brief Publication. 2017 Authors' conclusions Health Problem: Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting 6% to 20% of women of reproductive age. It is characterized by oligoovulation (menstrual irregularity), hyperandrogenism (increased testosterone levels), and polycystic ovaries

2017 Health Technology Assessment (HTA) Database.

6. Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis

Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go to . Clipboard, Search History, and several other (...) characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Stroke Actions , 51 (2), 666-669 Feb 2020 Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis , , , , , , Affiliations Expand Affiliations 1 From the Department of Advanced Medical

2020 EvidenceUpdates

7. A Transdermal Glucagon Patch for Severe Hypoglycemia

A Transdermal Glucagon Patch for Severe Hypoglycemia A Transdermal Glucagon Patch for Severe Hypoglycemia | CADTH.ca CADTH Document Viewer A Transdermal Glucagon Patch for Severe Hypoglycemia Table of Contents Search this document A Transdermal Glucagon Patch for Severe Hypoglycemia June 2017 Summary The ZP-Glucagon patch uses novel microneedle technology to deliver glucagon through the skin to people who are experiencing severe hypoglycemia (very low blood sugar). There is very limited (...) evidence, from one small study, comparing the ZP-Glucagon patch with glucagon injected intramuscularly. The evidence suggests that the correction of blood sugar levels is comparable between the ZP-Glucagon patch and the glucagon injected intramuscularly when tested in a controlled setting. The ZP-Glucagon patch is not yet commercially available and the anticipated cost is unknown. In an emergency situation, the ZP-Glucagon patch may be a more user-friendly option than injecting glucagon. Issue

2017 CADTH - Issues in Emerging Health Technologies

8. A Transdermal Glucagon Patch for Severe Hypoglycemia

A Transdermal Glucagon Patch for Severe Hypoglycemia A Transdermal Glucagon Patch for Severe Hypoglycemia | CADTH.ca CADTH Document Viewer A Transdermal Glucagon Patch for Severe Hypoglycemia Table of Contents Search this document A Transdermal Glucagon Patch for Severe Hypoglycemia June 2017 Summary The ZP-Glucagon patch uses novel microneedle technology to deliver glucagon through the skin to people who are experiencing severe hypoglycemia (very low blood sugar). There is very limited (...) evidence, from one small study, comparing the ZP-Glucagon patch with glucagon injected intramuscularly. The evidence suggests that the correction of blood sugar levels is comparable between the ZP-Glucagon patch and the glucagon injected intramuscularly when tested in a controlled setting. The ZP-Glucagon patch is not yet commercially available and the anticipated cost is unknown. In an emergency situation, the ZP-Glucagon patch may be a more user-friendly option than injecting glucagon. Issue

2017 CADTH - Issues in Emerging Health Technologies

9. Renal potassium handling in carriers of the Gly40Ser mutation of the glucagon receptor suggests a role for glucagon in potassium homeostasis Full Text available with Trip Pro

Renal potassium handling in carriers of the Gly40Ser mutation of the glucagon receptor suggests a role for glucagon in potassium homeostasis Plasma potassium concentration (PK ) is tightly regulated. Insulin is known to favor potassium entry into cells. But how potassium leaves the cells later on is not often considered. Previous studies in rats showed that glucagon infusion increased urinary potassium excretion dose-dependently and reversibly. This prompted us to investigate the possible (...) influence of glucagon on potassium handling in humans. We took advantage of the Gly40Ser mutation of the glucagon receptor (GR) that results in a partial loss of function of the GR. In the Olivetti cohort (male workers), 25 subjects who carried this mutation were matched 1:4 to 100 noncarriers for age and weight. Estimated osmolarity of serum and 24-h urine (Sosm and Uosm, respectively) was calculated from the concentrations of the main solutes: [(Na+K)*2 + urea (+glucose for serum)]. Transtubular

2018 Physiological reports

10. Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus Full Text available with Trip Pro

Coagonist of glucagon-like peptide-1 and glucagon receptors ameliorates kidney injury in murine models of obesity and diabetes mellitus To investigate the role of glucagon-like peptide-1 (GLP-1)/glucagon receptors coagonist on renal dysfunction associated with diabetes and obesity.Chronic high-fat diet fed C57BL/6J mice, streptozotocin-treated high-fat diet fed C57BL/6J mice and diabetic C57BLKS/J db/db mice were used as models of diabetes-induced renal dysfunction. The streptozotocin-treated (...) high-fat diet fed mice and db/db mice were treated with the GLP-1 and glucagon receptors coagonist (Aib2 C24 Chimera2, 150 μg/kg, sc) for twelve weeks, while in chronic high-fat diet fed mice, coagonist (Aib2 C24 Chimera2, 150 μg/kg, sc) treatment was continued for forty weeks. Kidney function, histology, fibrosis, inflammation, and plasma biochemistry were assessed at the end of the treatment.Coagonist treatment decreased body weight, plasma lipids, insulin resistance, creatinine, blood urea

2018 World journal of diabetes

11. Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases Full Text available with Trip Pro

Glucagon-Like Peptide-1 Receptor Agonist and Glucagon Increase Glucose-Stimulated Insulin Secretion in Beta Cells via Distinct Adenylyl Cyclases Diabetes mellitus is a chronic disease in which the pancreas no longer produces enough insulin. Pancreatic alpha cell mass increases in response to insufficient insulin secretion. However, the reason for this increase is not clear. It is possible that the increased alpha-cells may stimulate compensatory insulin release in response to the insufficient (...) insulin such as insulin resistance. In this study, we investigated whether glucagon and glucagon-like peptide-1 (GLP-1), hormones produced by alpha cells, contribute to insulin secretion in INS-1 cells, a beta cell line. We confirmed that alpha cell area in the pancreatic islets and glucagon secretion were increased in HFD-induced obese mice. Co-treatment with glucagon and exendin-4 (Ex-4), a GLP-1 receptor agonist, additively increased glucose-stimulated insulin secretion in INS-1 cells. In parallel

2018 International journal of medical sciences

12. Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. Full Text available with Trip Pro

Glucagon like receptor 1/ glucagon dual agonist acutely enhanced hepatic lipid clearance and suppressed de novo lipogenesis in mice. Lipid lowering properties of glucagon have been reported. Blocking glucagon signaling leads to rise in plasma LDL levels. Here, we demonstrate the lipid lowering effects of acute dosing with Glp1r/Gcgr dual agonist (DualAG). All the experiments were performed in 25 week-old male diet-induced (60% kCal fat) obese mice. After 2 hrs of fasting, mice were injected (...) glucagon signaling and are liver centric.

2017 PLoS ONE

13. A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Full Text available with Trip Pro

A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. To evaluate the safety, pharmacokinetics and pharmacodynamics of SAR425899, a novel polypeptide, active as an agonist at both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCR), in healthy volunteers and in overweight/obese patients with type 2 diabetes (T2D).Subcutaneous administrations of SAR425899 were

2018 obesity & metabolism Controlled trial quality: uncertain

14. Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. Full Text available with Trip Pro

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2. The intestine is highly efficient at absorbing and packaging dietary lipids onto the structural protein apoB48 for distribution throughout the body. Here, we summarize recent advances into understanding the physiological and pharmacological actions of the proglucagon-derived peptides: glucagon like peptide 1 (GLP-1) and glucagon like peptide 2 (GLP-2

2018 Current Opinion in Lipidology

15. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Full Text available with Trip Pro

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and without established atherosclerotic

2019 EvidenceUpdates

16. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy (Abstract)

Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy To evaluate the safety and efficacy of IONIS-GCGRRx, a 2'-O-methoxyethyl antisense oligonucleotide targeting the glucagon receptor (GCGR), and the underlying mechanism of liver transaminase increases in patients with type 2 diabetes on stable metformin therapy.In three phase 2, randomized, double-blind (...) of transaminase increases.IONIS-GCGRRx is a potent inhibitor of hepatic glucagon receptor expression with a potential to improve glycemic control at low weekly doses in combination with metformin. Significant reductions in HbA1c occurred across the full-dose range tested, with minimal transaminase elevations at lower doses. Furthermore, novel results suggest that despite inhibition of glycogenolysis after GCGR antagonism, IONIS-GCGRRx did not increase hepatic glycogen content.© 2019 by the American Diabetes

2019 EvidenceUpdates

17. Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis Full Text available with Trip Pro

Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis To compare the cardiovascular efficacy and safety of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) in adults with Type 2 diabetes.Electronic databases were searched from inception to 22 October 2018 for randomized controlled trials designed to assess

2019 EvidenceUpdates

18. Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist Full Text available with Trip Pro

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated alanine aminotransferases (ALTs) associated with LY2409021. Patients participated in a 6 (...) and/or TM6SF2 variant alleles are at risk for hepatic steatosis and elevated ALT levels caused by LY2409021, a glucagon receptor antagonist. More studies are needed to investigate if our observations are generalizable to hepatic steatosis caused by other medications. (Hepatology Communications 2018;2:561-570).

2018 Hepatology communications Controlled trial quality: uncertain

19. Glucagon-Like Peptide-1 receptor analogues

Glucagon-Like Peptide-1 receptor analogues www.sps.nhs.uk | Published December 2016 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice www.sps.nhs.uk | Published December 2016 2 Metformin Sulphonylurea Pioglitazone Sulphonylurea & Pioglitazone Metformin & Pioglitazone Basal Insulin + Metformin Basal Insulin + Sulphonylurea Basal Insulin + pioglitazone Basal Insulin + metformin + pioglitazone L L L L L NICE (...) monitoring and subsequent dose adjustment on an individual level Licensing(L)/NICE Approval(N) Hypoglycaemic events According to NICE's meta-analysis, three non- insulin based drug combinations (including 2nd intensification with GLP-1 analogues) were generally associated with less hypoglycaemic events compared to the metformin-NPH insulin combination. Not addressed by NICE guidance London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues Basal Insulin In adults with type

2017 Specialist Pharmacy Services

20. Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness

Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Epinephrine versus Glucagon for the Management of Severe Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Epinephrine versus Glucagon for the Management of Severe (...) Hypoglycemia in Insulin-Dependent Patients: Clinical and Cost-Effectiveness Published on: September 30, 2015 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? What is the cost-effectiveness of epinephrine compared with glucagon for the management of severe hypoglycemia in insulin-dependent patients? Key Message

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>